As ONCO Assist in DEPTH, we ensure the detection of cancer-specific changes with genetic tests. In this way, we aim to increase the success of treatment and personalize cancer treatment by specialist physicians.
Our mission is to open a new era in the fight against cancer with early diagnosis and personalized medicine.
Because we care about lives...
Who Are We?
ABOUT US
“Cancer is a preventable and manageable disease with early diagnosis”
Cancer is a disease that develops mostly as a result of genetic mutations accumulated over a lifetime; however, a certain proportion is associated with hereditary predispositions. In individuals with a family history of cancer, the risk of having a predisposition to this disease cannot be ignored. Assessing this risk is possible by examining cancer-related genes identified in scientific studies. Using the latest technology and scientific research, our team of experts assesses the risk of cancer based on the genetic profile of the individual and enables you to take early measures. Today, familial cancer screening can be performed with just one tube of blood thanks to new generation sequencing technologies.
Somatic Tumor Panel
Pathological and genetic analyses of cancer tissue samples are critical for determining the use of targeted therapies, immunotherapy and smart drugs, and for directing patients to clinical trials. The success of new and effective drugs is often associated with concurrent chemotherapy and radiotherapy. Genetic profiling can show which treatment options are appropriate for patients, as well as which treatments should be avoided.
Liquid Biopsy
Some tumors may not be suitable for traditional biopsy intervention due to their location or structure. This can make tumor profiling difficult. However, the genetic material released into circulation by cancer cells can be detected and analyzed by liquid biopsy, a non-invasive method. Liquid biopsy is an important tool not only for monitoring the treatment process but also for assessing the risk of disease recurrence. The possibility of relapse can be screened with this method and preventive measures can be taken before relapse occurs.
Biomarker Tests
By examining specific genes or chromosomal changes, biomarker tests provide important information to shape a patient's treatment plan. Unlike panels, biomarker tests are more rapid, targeted and drug-oriented assays.
Who Are We?
Founded in 2018, Pharmackt operates in the Turkish pharmaceutical and genetic markets. In oncology, hematology and rare diseases, “Pharmackt” sees it as a priority to be useful in every field with its innovative approaches in order to produce common solutions to the search of physicians and patients.